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Isothiocyanates are detected in 
human synovial fluid following 
broccoli consumption and can 
affect the tissues of the knee joint
Rose Davidson  1, Sarah Gardner1, Orla Jupp1, Angela Bullough2, Sue Butters2, Laura Watts2, 
Simon Donell2, Maria Traka3, Shikha Saha3, Richard Mithen3, Mandy Peffers4, Peter Clegg4, 
Yongping Bao5, Aedin Cassidy5 & Ian Clark1
Osteoarthritis is a major cause of disability and there is no current pharmaceutical treatment which can 
prevent the disease or slow its progression. Dietary advice or supplementation is clearly an attractive 
option since it has low toxicity and ease of implementation on a population level. We have previously 
demonstrated that sulforaphane, a dietary isothiocyanate derived from its glucosinolate precursor 
which is found in broccoli, can prevent cartilage destruction in cells, in in vitro and in vivo models of 
osteoarthritis. As the next phase of this research, we enrolled 40 patients with knee osteoarthritis 
undergoing total knee replacement into a proof-of-principle trial. Patients were randomised to either a 
low or high glucosinolate diet for 14 days prior to surgery. We detected ITCs in the synovial fluid of the 
high glucosinolate group, but not the low glucosinolate group. This was mirrored by an increase in ITCs 
and specifically sulforaphane in the plasma. Proteomic analysis of synovial fluid showed significantly 
distinct profiles between groups with 125 differentially expressed proteins. The functional consequence 
of this diet will now be tested in a clinical trial.
Osteoarthritis (OA) of the hip or knee is ranked as 11th of 291 conditions that contribute to global disability; and 
the consequent years lived with disability (YLDs) are estimated to have risen by 61% from 1990–20101. There 
are no disease-modifying OA drugs (DMOADs) currently available, and pharmacological interventions provide 
symptomatic relief only, which is frequently insufficient2, 3.
The National Institute for Health and Care Excellence (NICE) and the American College of Rheumatology 
both recommend OA management strategies based upon activity and exercise, and weight loss if overweight or 
obese. A third core treatment area recommended by NICE focuses on information to support self-management4, 5. 
Within these core treatment areas, dietary and exercise advice have been identified as cost effective approaches 
to the treatment of OA6.
We and others have shown previously that sulforaphane (1-isothiocyanato-4-methylsulfinylbutane, SFN) 
is a chondroprotective agent in vitro and in vivo7–10. SFN is derived from a precursor, glucoraphanin, gained 
from eating brassicas, particularly broccoli. Sulforaphane has broad biological activity and its role in joint health 
was recently reviewed11. SFN can repress the expression of key metalloproteinases implicated in OA7, 10, regu-
late NF-κB and Nrf2 signalling, inhibit production of prostaglandin E2 and nitric oxide in chondrocytes7, 9, 10 
and prevent cytokine-induced cartilage destruction in vitro9, 10. In vivo, SFN reduces cartilage destruction in 
the ‘destabilisation of the medial meniscus’ (DMM) murine model of OA10 and inhibits synovial hyperplasia 
in collagen-induced arthritis (CIA)8. Nrf2 knockout mice also showed increased cartilage lesions and oxidative 
damage in antibody-induced arthritis (AIA)12.
The pharmacokinetics of SFN has been studied, with one report measuring the average peak plasma con-
centration of SFN (2.2 µM) approximately 2 hours following consumption of 100 g of broccoli florets prepared 
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as a soup. This increased to 7.3 µM following consumption of a high glucoraphanin variety of broccoli13. There 
is no evidence that normal dietary intake of broccoli is associated with toxicity, even in the long term. SFN has 
also been shown to accumulate intracellularly via conjugation to glutathione giving millimolar intracellular con-
centrations in a cell-type dependent manner14. We showed an accumulation of SFN-glutathione (SFN-GSH) in 
primary chondrocytes of >10-fold and >100-fold in the SW1353 cell line10. There are no publications describing 
the detection of dietary isothiocyanates (ITCs) in the knee joint.
The aim of this study was firstly to determine whether ITCs could be detected in the synovial fluid of OA 
patients following a glucosinolate (broccoli)-rich diet and secondly to identify changes in the joint tissues.
Patients and Methods
Participants. Osteoarthritis patients referred for total knee replacement (TKR) to the Norfolk and Norwich 
University Hospital (NNUH), Norwich, UK, were screened for recruitment onto the study using the eligibility 
criteria in Table 1. Eligible patients were male or post-menopausal females scheduled for a TKR willing to comply 
with the dietary intervention. This study was approved by the National Research Ethics Service Committee East 
of England, Cambridge South, UK (approval number 2012ORTH06L (104-07-12)). All patients gave informed 
written consent. All methods were performed in accordance with relevant laboratory guidelines and institutional 
regulations.
Study design. This was a proof-of-principle; randomised controlled trial designed to test whether bioactive 
molecules derived from broccoli, eaten prior to joint replacement, can be detected in the articular joint and 
mediate changes.
Patients followed a 7-day washout period, (no consumption of broccoli, cabbage, cauliflower, arugula 
(rocket), canola/rapeseed, Brussels sprouts, radish, horseradish, kale, turnip root, greens, watercress, pak choi, 
collard greens, rutabaga (swede) vegetables). The washout diet was either continued (low glucosinolate group) 
or patients consumed 100 g of a high glucosinolate broccoli15 per day for 14 days prior to TKR (high gluco-
sinolate group). Patients were allocated to a high or low glucosinolate group by block randomisation (blocks 
of five). The trial nurses screened and recruited patients and were blinded to the pre-allocated study numbers. 
Throughout the study, patients had telephone access to a trial nurse for advice and received a telephone call to 
monitor compliance.
Blood was sampled at the end of the washout period (baseline) and collected into K2EDTA. Patients allocated 
to the high glucosinolate group were given written instructions, a vegetable steamer and a demonstration for 
preparation of the broccoli. All patients were given a validated 7-day food diary with guidance for completion. A 
second blood sample was taken on the day of TKR surgery. Synovial fluid, cartilage and fat tissues were obtained 
at surgery. Synovial fluid was aspirated into a sterile, pre-chilled container immediately prior to surgery, taking 
care to avoid blood contamination. Cartilage and fat tissues were removed as routine for TKR and immediately 
placed into separate containers with pre-chilled, sterile phosphate buffered saline (PBS). All tissue samples were 
transported at 4 °C in sterile conditions and processed or stored within 1 hour. Synovial fluid was centrifuged at 
200 g, 5 minutes at 4 °C and the supernatants stored at −80 °C. Undamaged cartilage was dissected at full thick-
ness from the bone, and both cartilage and fat were snap frozen and stored at −80 °C for RNA extraction, or 
placed directly into culture for in vitro degradation analysis.
Blood plasma and synovial fluid were analysed for ITC levels. Analyses of synovial fluid proteomics, in vitro 
cartilage degradation, joint tissue gene expression profiling and GST genotyping were performed.
Inclusion criteria Exclusion criteria
Males and post-menopausal females Those with known allergies to the dietary compounds/foods/commercially available supplements
OA patient scheduled for total knee replacement
Those unprepared to adhere to dietary restrictions during the 
trial. i.e. wash out period, consumption of standardised food/
commercial supplement
Radiological evidence of some cartilage tissue 
remaining in the joint to be replaced
Those unwilling to consent to blood sampling or, use of their 
joint tissues for analysis
Normal biochemical, haematological or urinary 
assessment as determined by clinical assessor. Full 
blood count
Participation in another dietary intervention trial running 
concurrently.
Willingness to comply with dietary requirements Those taking other food supplements unless they are prepared to abstain during the trial.
Abnormal biochemical, haematological or urinary assessment 
indicating abnormal renal or liver function.
Smokers or those ceasing <3 mths ago
Pre-menopausal women
Rheumatoid arthritis, inflammation or sepsis
Patients taking warfarin medication
Table 1. Eligibility for study screening criteria. Patients scheduled for total knee replacement due to 
osteoarthritis were screened for eligibility to participate in the study. The inclusion and exclusion criteria are 
shown. Low glucosinolate diet n = 20, high glucosinolate diet n = 20.
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Isothiocyanate detection. Isothiocyanates were detected as described previously13, 15–17.
Isothiocyanate detection: Broccoli. Isothiocyanates were detected as described15, 16. No vicinal dithiol 
contamination of equipment or materials was detected (data not shown). Control samples contained neither 
broccoli extracts nor 1,2-benzenedithiole (1,2 BDT). High glucosinolate frozen broccoli (100 g) was steamed for 
6 mins and blended (0.5 g/ml) in phosphate buffer (33 mM potassium phosphate, 500 µM ascorbic acid, 1 mM 
EDTA). The broccoli blend was diluted 1:1.5 in distilled water and glucosinolates were hydrolysed using thio-
glucosidase, 0.05 U/ml (Sigma T4528) at room temperature, 2 hours. The blend was clarified by centrifugation 
at 3000 g, 5 min and the supernatant was filtered through Whatman no. 41 filter paper, pre-soaked in phosphate 
buffer. Extraction was repeated three times and pooled. A cyclocondensation reaction of 1,2 BDT and broccoli 
extracts to 1,3 benzodithiole-2-thione (1,3-BDT) was performed at 65 °C for 2 hours in the dark: the broccoli 
extract was diluted 1:9 in 100 mM potassium phosphate buffer, pH8.5 and added 1:1 to 8 mM 1,2 BDT dissolved 
in 100% v/v methanol. The 1,3-benzodithiole-2-thione product was detected at 365 nm.
Isothiocyanate detection: Plasma. Plasma was deproteinised with a 6% w/v final concentration of pol-
yethylene glycol (PEG) 8000 for 10 mins, at 4 °C, in the dark. Plasma was centrifuged 20 000 g, 5 mins, 4 °C. 
Supernatant was diluted 1:1 in 100 mM potassium phosphate buffer, pH8.5 with 2x volumes 20 mM 1,2 BDT. 
Samples were briefly vortexed and then incubated at 65 °C, 2 hours in the dark, followed by centrifugation at 20 
000 g for 6 mins, 4 °C. Supernatants were diluted 1:1 in distilled water and purified using solid phase extraction 
(SPE, C18 Bond Elut, Agilent). The SPE column was activated with 1x vol 100% v/v acetonitrile, 2x vol 25% v/v 
acetonitile and washed with 2x vols distilled water. Samples were washed x3 using 30% v/v propan-2-ol and eluted 
with 100% v/v acetonitrile. Reversed phase HPLC was carried out using a Luna® C18 (2) 100 Å, LC Column 
(5 µm, 150 × 4.60 mm, Phenomenex) at 37 °C using an isocratic mobile phase of 80% v/v methanol, 20% v/v water 
at a flow rate of 1 ml/min. 1,3 BDT was detected using a SPD-M2OA Prominence HPLC photo diode array detec-
tor (Shimadzu) at 365 nm. Sensitivity of the assay in plasma was 6 pmols.
Sulforaphane detection: Plasma. Plasma samples were analysed for SFN and its conjugates using a 
method that has been described previously [13] with slight modifications. Briefly plasma samples (100 µl) were 
prepared by adding 20 µl precooled (4 °C) trichloroacetic acid followed by centrifugation at 11 600 g at 4 °C 
for 10 min. The injection volume was 5 µl, the HPLC column was a Luna (3 µm particle size, 100 × 2 mm from 
Phenomenex) using mobile phase flow 0.25 ml/min, the mobile phase were consisted of ammonium acetate buffer 
(13 mmol/L, pH4; solvent A) and acetonitrile plus 0.1% acetic acid (solvent B) in a linear gradient from 5% B to 
35% B over 5 min with 6 min re equilibration time. Agilent 6490 Mass spectrometry analysis was performed with 
the use of electrospray ionization in positive ion mode with nitrogen gas and nitrogen sheath gas temperatures 
160 °C and 400 °C, respectively, gas flow 16 l/min, Nebulizer pressure 30 psi, sheath gas flow 12 l/min and capillary 
voltage 4000 V.
Isothiocyanate detection: Synovial fluid. Synovial fluid was diluted in water if necessary and processed 
as for plasma with the inclusion of at least 10 mins centrifugation following the deproteinisation step. Sensitivity 
of the assay in synovial fluid was 3.8 pmols.
Proteomic analysis of synovial fluid. A subset of 18 synovial fluid samples were prepared as described 
previously18. Briefly, samples were hyaluronidase treated, filtered and total protein quantified using Bradford 
reagent. Synovial fluid samples containing 6 mg total protein were enriched for low abundance proteins using 
ProteoMiner™ Small Capacity kit (BioRad) according to the manufacturer’s instructions and analysed by 
SDS-PAGE.
For LC-MS/MS, samples were trypsin digested and loaded on a 2 hour gradient LC-MS/MS analysis using 
a NanoAcquity™ ultra-performance LC (Waters) and LTQ-Orbitrap-Velos (Thermo-Fisher Scientific)19. One 
sample was excluded for technical reasons (blebbing).
Progenesis™ LC-MS software (Waters, Manchester, UK) was used for label-free quantification18. Data were 
searched using Mascot against the Unihuman Reviewed database. Peptide matches above an identity threshold 
were adjusted to give a false discovery rate (FDR) of 1% before the protein identifications being re-imported into 
Progenesis-QI™. Adjusted ANOVA values of p < 0.05 and regulation of >2-fold were regarded as significant. 
Neopeptides were identified as previously described adjusted to 1% FDR20.
In vitro cartilage degradation. Cartilage was dissected into ~5 mm3 chips and cultured overnight in quad-
ruplicate in Dulbecco’s modified Eagle’s medium (DMEM; GlutaMAX) supplemented with 1,000 IU/ml penicil-
lin, and 100 µg/ml streptomycin at 37 °C, 5% v/v CO2. Culture media were refreshed at day 1 and day 7, with an 
overall culture of 14 days. Remaining cartilage was papain digested. Culture media and digested cartilage were 
analysed for glycosaminoglycan and hydroxyproline content as described21, 22.
Gene expression analysis. Cartilage (200 mg) was crushed under liquid nitrogen to a fine powder and total 
RNA was extracted using TRIzol® reagent (Invitrogen) and RNeasy mini kit (Qiagen), as described23, 24.
Approximately 100 mg of fat tissue was homogenised in 600 µl RLT buffer (Qiagen) using the TissueLyser LT 
(Qiagen) and spherical ball bearings. Total RNA was extracted using the RNeasy mini kit (Qiagen) according to 
the manufacturer’s instructions.
RNA was quantified using the NanoDrop 2000 spectrophotometer (Thermo Scientific) and the quality 
assessed using the Experion RNA StdSens analysis kit (Bio-Rad). cDNA was synthesised using 500 ng of RNA 
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and Superscript II reverse transcriptase (Invitrogen) with random hexamers according to the manufacturer’s 
instructions.
Relative quantification of gene expression was measured using the 7900HT Fast Real Time PCR System 
(Applied Biosystems) and a custom designed Taqman Low Density Array (TLDA). Genes were selected by analy-
sis of microarray data from SFN treated SW1353 cells, primary human articular chondrocytes and human articu-
lar cartilage explants (data not shown). Assay details are included in Supplementary Table S1. Cycling conditions 
were 50 °C, 20 s, 95 °C, 10 min, 95 °C, 15 s, and 60 °C, 1 min × 40 cycles. Data were analysed using DataAssist 
Software v3.01 (Life Technologies), normalised to 18 S rRNA and expressed as 2−ΔCt.
Biomarkers. Plasma samples were analysed for Coll 2-1, (a peptide from the triple helix of type II colla-
gen) using ELISA25, and hsCRP (high sensitivity C-reactive protein) using a particle-enhanced immunoturbi-
dimetric assay. Analyses were performed by the Bioanalytical Facility (BAF) at the University of East Anglia. 
Synovial fluid samples were analysed for cytokine protein expression using the Cytometric Bead Array Flex Set 
(BD Biosciences) and was performed by Flow Cytometry Services, University of East Anglia.
Diet diary. All patients completed a validated 7-day food diary26. Dietary data was analysed using WISP V4.0 
(Tinuviel Software).
Genotyping. DNA was extracted from plasma using QIAamp DNA Blood Mini Kit (Qiagen) according 
to manufacturer’s instructions. Copy number variation for members of the glutathione S-transferase super-
family, (GSTP1, GSTM1 and GSTT1) was detected using TaqMan® Copy Number Assays (Life Technologies 
cat: Hs01541162_cn, Hs02575461_cn, Hs00010004) and analysed using CopyCaller® software v2.0 (Life 
Technologies).
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Statistical testing. High and low glucosinolate groups were compared using unpaired t-test (two tailed) 
and when applied, false discovery rate (FDR) was calculated using the Benjamini-Hochberg FDR method. It was 
noted that within the plasma samples of the low glucosinolate group, all except five samples of the post inter-
vention samples had undetectable levels of SFN. Undetected points were treated as zero for the comparisons of 
plasma ITCs or SFN, and synovial fluid ITC. Since ITCs were not detected in the low glucosinolate group of the 
synovial fluid samples, no statistical testing was performed. Differences observed between groups remains the 
same and conclusions are also identifical using ‘limit of detection’ values instead of zero. All data was analysed 
using GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego California USA, unless other-
wise stated in the methods. Graphpad Prism calculated descriptive statistics to include confidence intervals and 
normality testing (D’Agostino & Pearson omnibus normality test). Data with non-Gaussian distribution were 
transformed prior to further statistical testing. A p value < 0.05 was considered significant.
Ethics approval. This study protocol was approved by the NRES Committee East of England, Cambridge 
South, UK.
Results
Patients and baseline characteristics. A total of 268 patients were screened for eligibility where 143 
(53%) were eligible, of which 40 patients (15%) were recruited. A flow diagram to show the process of recruitment 
and parallel randomisation of the trial is shown in Fig. 1, and more details are given in Supplementary Table S2. 
Drug use was not recorded. Patient characteristics were males n = 17, (low glucosinolate 7, high glucosinolate 
10,), females n = 20 (low glucosinolate 13, high glucosinolate 7). Low glucosinolate group median age 71 (range 
50–89), high glucosinolate group median age 73 (range 58–84).
Isothiocyanate levels in plasma and synovial fluid. Total ITCs measured in the high glucosinolate 
broccoli were 1.8 µmols g−1, so patients consumed 180 µmols per day. Patients in the high glucosinolate group 
attained greater increases in plasma total ITC concentrations between baseline and post-intervention: high glu-
cosinolate group (mean fold change: 2.20, 95% CI: 1.45 to 2.92) compared to the low glucosinolate group (mean 
fold change: 0.90, 95% CI: 0.68 to 1.12), p < 0.0001 (Table 2). This confirmed compliance with the intervention. 
Sulforaphane was also significantly increased in the plasma of the high glucosinolate group (mean change: 0.32, 
95% CI: 0.20 to 0.44) compared to low glucosinolate (mean change: 0.02, 95% CI: −0.01 to 0.04), p < 0.0001 
(Table 2); since SFN in many post-intervention samples in the low glucosinolate group was undetected and there-
fore treated as zero, fold change cannot be calculated. Importantly, ITCs were detected in the synovial fluids of 
the high glucosinolate group (mean 496.6 nM, 95% CI: 419.1 to 574.2) but not in the low glucosinolate group 
(Table 2). Mean total ITCs and SFN measured in the plasma of the high glucosinolate group (post intervention) 
were 2.22 µM, 95% CI: 1.19 to 3.24 and 0.32 µM, 95% CI: 0.20 to 0.44 respectively) (Table 2). Data do not segregate 
on the basis of gender.
Proteomics. Peptides identified by LC-MS/MS in the synovial fluid samples (low glucosinolate n = 8, high 
glucosinolate n = 9) were analysed using Progenesis™ QI software (Waters, Manchester, UK). 382 quantifiable 
proteins were identified, 348 with >1 peptide. One hundred and twenty-five proteins were identified with >1 
peptide and differentially expressed between high and low glucosinolate diets (p < 0.05, 1% FDR). An FDR of 5% 
revealed 29 differentially expressed proteins identified by >1 peptide with a minimum fold change of >2. In the 
high glucosinolate group 18 proteins had decreased expression whilst 11 proteins were increased compared to the 
www.nature.com/scientificreports/
5Scientific RepoRts | 7: 3398  | DOI:10.1038/s41598-017-03629-5
low glucosinolate group. Twelve proteins are commonly found in plasma, 10 of which were decreased in the high 
glucosinolate group (Table 3). Aside from common plasma proteins, the top four differentially expressed pro-
teins, were neuroblastoma suppressor of tumorigenicity 1 (NBL1), histidine protein methyltransferase 1 homolog 
(METTL18), calreticulin (CALR) and SWI/SNF complex subunit SMARCC1 (SMARCC1) each p < 0.0001.
Neopeptides. Neopeptides identified in synovial fluid unique to high and low glucosinolate groups were 
identified for aggrecan, biglycan, decorin, fibromodulin, cartilage oligomeric matrix protein and a number of 
collagens.
There was no correlation between diet and neopeptide abundance, (an indicator of proteolysis), in synovial 
fluid (see Supplementary Table S3). This holds true whether considering neopeptides unique or common to either 
intervention.
Figure 1. A flow diagram to show the process of enrolment and parallel randomisation for the primary 
outcome.
Outcome
Low glucosinolate 
Mean (95%CI)
High glucosinolate 
Mean (95%CI) p-value
ITC synovial fluid (nM) n.d 496.6 (419.10 to 574.20) —
ITC plasma (fold change) 0.90 (0.68 to 1.12) 2.20 (1.45 to 2.92) <0.0001
SFN plasma (change) 0.02 (−0.01 to 0.04) 0.32 (0.2 to 0.44) <0.0001
ITC plasma (µM) baseline 1.71 (1.10 to 2.33) 1.17 (0.69 to 1.64) —
ITC plasma (µM) post 
intervention 1.36 (0.86 to 1.87) 2.22 (1.19 to 3.24) —
SFN plasma (µM) baseline n.d 0.004 (−0.004 to 0.012 —
SFN plasma (µM) post 
intervention 0.02 (−0.005 to 0.04) 0.32 (0.20 to 0.44) —
Table 2. Isothiocyanate levels in synovial fluid and plasma. Total isothiocyanates (ITCs) measured in synovial 
fluid and plasma, and the specific metabolite sulforaphane (SFN) measured in plasma from low and high 
glucosinolate groups. Fold change: post intervention/baseline, Change: post intervention – baseline, low 
glucosinolate n = 20, high glucosinolate n = 17, n.d – not detected. Mean values with 95% confidence intervals 
and p-values are given.
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In vitro cartilage degradation. No significant differences were observed for in vitro rates of cartilage deg-
radation (glycosaminoglycan and hydroxyproline loss) between the high and low glucosinolate interventions 
(Table 4).
Gene Expression. Gene expression was measured by TLDA in cartilage (low glucosinolate n = 20, high glu-
cosinolate n = 17) and fat (low glucosinolate n = 13, high glucosinolate n = 10) tissues. Adjustment for multiple 
testing by controlling the false discovery rate (5%) generated no significant differences between groups for either 
tissue (Supplementary Table S4).
However, unadjusted data showed that in cartilage HERC5 (HECT and RLD Domain Containing E3 Ubiquitin 
Protein Ligase 5) (p = 0.009) and LUM (lumican) (p = 0.05) were decreased in the high glucosinolate group. IL-1β 
(interleukin 1β) (p = 0.01) and IGFBP4 (Insulin-Like Growth Factor Binding Protein 4) (p = 0.03) were increased 
in the high glucosinolate group. Taking large fold changes into account CCL7 (Chemokine (C-C Motif) Ligand 
7) (p = 0.06) and SFRP1 (Secreted Frizzled-Related Protein 1) (p = 0.06) showed tendencies to decreased and 
increased expression respectively in the high glucosinolate group. In fat tissue CXCL10 (Chemokine (C-X-C 
Motif) Ligand 10) (p = 0.03) was decreased in the high glucosinolate group whilst IRX3 (Iroquois Homeobox 3) 
(p = 0.06) was increased.
Description Accession
Peptide 
count
Unique 
peptides q-value
Mean FC 
(H/L) Ref
Neuroblastoma suppressor of 
tumorigenicity 1 (NBL1) P41271 2 2 1.26E-07 0.33
34
Histidine protein methyltransferase 1 
homolog (METTL18) O95568 2 1 2.50E-06 3.29
Calreticulin (CALR) P27797 2 2 1.37E-05 0.28
SWI/SNF complex subunit SMARCC1 
(SMARCC1) Q92922;Q9UL12 2 1 2.17E-05 0.31
Collagen alpha-1(VI) chain (COL6A1) P12109 3 2 8.15E-05 0.47 33, 34
Adenylyl cyclase-associated protein 
1 (CAP1) Q01518 2 1 1.41E-04 1.0E-06
Kinesin-like protein KIF26B (KIF26B) Q2KJY2 3 1 1.08E-03 15.12
Tubulin alpha-1B chain (TUBA1B) P68363;A6NHL2;P68366;Q13748;Q71U36 4 4 2.75E-03 2.27
Adiponectin (ADIPOQ) Q15848 2 2 3.90E-03 0.19 34
Integrin beta-like protein 1 (ITGBL1) O95965 3 3 5.22E-03 0.39
Thrombospondin-3 (THBS3) P49746 3 1 6.51E-03 5.85 34
Coronin-1A (CORO1A) P31146 8 8 6.69E-03 3.47
Golgin subfamily B member 1 
(GOLGB1) Q14789 3 2 7.33E-03 3.92
Collagen alpha-1(V) chain (COL5A1) P20908 3 2 1.03E-02 4.78 34
Neutrophil defensin 1 (DEFA1) P59665 3 3 1.53E-02 3.03
Ganglioside GM2 activator (GM2A) P17900 2 2 3.00E-02 3.28 34
Tumor necrosis factor-inducible gene 
6 protein (TNFAIP6) P98066 5 5 3.19E-02 0.43
34
Common plasma proteins
Apolipoprotein A-II (APOA2) P02652 8 7 3.82E-09 0.34 33, 35
Alpha-1-antitrypsin (SERPINA1) P01009 17 17 1.52E-07 0.33 34, 35
Vitamin K-dependent protein Z 
(PROZ) P22891 9 9 1.85E-06 0.32
34
Plasma protease C1 inhibitor 
(SERPING1) P05155 7 5 7.53E-06 0.41
34, 35
Haemopexin (HPX) P02790 3 3 3.87E-05 0.39 33, 35
Apolipoprotein C-I (APOC1) P02654 2 2 2.79E-04 0.18 33
Ig heavy chain V-III region VH26 P01764;P01768 3 1 4.35E-04 0.29
Ig kappa chain V-II region Cum P01614;P01617 3 1 4.15E-03 2.14
Ig kappa chain V-II region RPMI 6410 P06310;P01615;P01616 3 2 6.26E-03 0.34
Complement factor B (CFB) P00751 5 5 8.16E-03 0.47 34, 35
Fibrinogen gamma chain (FGG) P02679 28 27 1.14E-02 0.50 33–36
Ig mu heavy chain disease protein P04220 25 2 1.62E-02 5.16
Table 3. Differentially expressed proteins identified in synovial fluid. Differentially expressed proteins in 
synovial fluid identified by LC-MS/MS. The table shows proteins of interest and common plasma proteins with 
significantly different levels of expression in low and high glucosinolate groups. Proteins were identified with 
>1 peptide, >2 fold change and controlled for 5% FDR. The number of peptides identified for each protein 
and the number of unique peptides for each protein are indicated. Proteins previously identified in the synovial 
fluid are referenced. Low glucosinolate n = 8, high glucosinolate n = 9. q-values are shown, significance level is 
q < 0.05. Mean fold change (FC) is given, calculated as peptide abundance in high/low glucosinolate group.
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Plasma Biomarkers – hsCRP and Coll 2-1. The 14-day intervention did not alter levels of either hsCRP 
(with many samples undetected) or Coll 2-1 in plasma, or protein cytokine expression of IL-6, IL-8, IL-1, TNF, 
CCL5, in synovial fluid (Table 4).
Diet Diaries. Nutrient intakes were largely similar between groups however, a significant increased intake 
of vitamin C (p = 9.96 × 10−06) was observed following adjustment for multiple testing using a 1% FDR 
(Supplementary Table S5).
Genotyping. The overall frequency of GSTT1 copy number was measured at 3 (8.1%) 0 copies, 27 (73%) 
2 copies, and 7 (18.9%) 4 copies. The overall frequency of GSTM1 copy number was measured at: 17 (45.9%) 0 
copies, 18 (48.6%) 2 copies, and 2 (5.4%) 4 copies. The overall frequency of GSTP1 copy number was measured 
at: 18 (48.6%) 2 copies, 7 (18.9%) 3 copies, 10 (27%) 4 copies and 1 (2.7%) 5 copies. Predicted copy numbers were 
similar between the high and low glucosinolate groups and are detailed in Supplementary Table S6. No correla-
tion was observed between genotype and any outcome measure.
Adverse events. There was one serious adverse event of a fractured humerus considered unrelated to the 
intervention. In terms of minor events, one participant reported bloating (high glucosinolate group), although the 
participant continued with the intervention.
Discussion
Our results provide the first evidence that following broccoli intake, the bioactive constituent ITCs reach the 
synovial fluid at concentrations with biological impact on the articular joint tissues, and alter the synovial fluid 
protein profile. This study clearly demonstrates that a dietary bioactive with chondroprotective properties can 
penetrate the knee in osteoarthritis. These data support our previous mouse model work, where we showed that a 
SFN-rich diet can provide chondroprotection in a mouse model of OA, though SFN and its metabolites were not 
measured directly in the joint.
Mean total ITC levels were 4.47-fold lower in the synovial fluid than the plasma. The concentration of small 
molecules in synovial fluid often reflects that of plasma since permeability into synovial fluid occurs through 
free diffusion from the endothelium of the synovial microvasculature and surrounding interstitium. The syno-
vial lining has no basement membrane and therefore small molecule diffusion is limited only by the volume of 
intercellular space27, however, many non-steroidal anti-inflammatory drugs also show lower concentrations in 
synovial fluid than plasma28, 29. This reflects the kinetics of elimination of the drug, repeat administration and 
also protein binding. In this study we did not standardize the timing of broccoli intake compared to sampling of 
blood or synovial fluid. It is also possible that the diet modifies synovial fluid volume which was not monitored 
in this study, though this is unlikely to be significant. Plasma levels for ITCs and SFN were higher than expected 
given the limited available published data. In the current study the timing of the broccoli meal during the day 
was not controlled. This and possible differences in the rate of metabolism by each patient’s unique microbiome30 
may explain the greater variation observed for plasma ITC levels in the high glucosinolate group. Twelve of the 
29 synovial fluid proteins with significant difference between groups are commonly found in plasma, and 10 of 
Outcome
Low glucosinolate 
Mean (95%CI)
High glucosinolate Mean 
(95%CI) p-value
Cartilage matrix degradation
n 19 15
Glycosaminoglycan (% loss) 23.72 (19.58 to 27.87) 25.68 (21.21 to 30.14) 0.50
Hydroxyproline (% loss) 0.71 (0.47 to 0.96) 0.77 (0.50 to 1.03) 0.65
Biomarkers
n 20 17
hsCRP (fold change) −5.48 (−16.02 to 5.05) −5.49 (−26.90 to 15.93) 0.33
Col2-1 (fold change) 4.41 (−1.02 to 9.83) 13.21 (−11.85 to 38.27) 0.44
Cytokine protein expression
n 19 17
Interleukin 6 (pg/ml) 84.54 (64.36 to 104.7) 70.42 (53.08 to 87.76) 0.25
Interleukin 8 (pg/ml) 46.62 (30.00 to 63.23) 36.50 (26.94 to 46.07) 0.45
Interleukin 1 (pg/ml) 36.80 (36.59 to 37.00) 36.98 (36.72 to 37.25) 0.25
Tumor necrosis factor (pg/ml) 39.03 (38.70 to 39.37) 39.36 (39.13 to 39.60) 0.10
Chemokine (C-C Motif) ligand 
5 (pg/ml) 54.04 (43.39 to 64.69) 66.80 (31.05 to 102.6) 0.68
Table 4. In vitro cartilage degradation, biomarkers and cytokine profile. In vitro degradation of cartilage 
aggrecan and collagen were measured by glycosaminoglycan and hydroxyproline release into culture media. 
Remaining cartilage was digested and percentage degradation calculated. High sensitivity C reactive protein 
(hsCRP) and collagen type II (col 2-1) biomarkers for inflammation and collagen degradation were measured 
in plasma (mean fold change given). The protein expression levels of cytokines were profiled in synovial fluid. 
Mean values and 95% confidence intervals are shown. P-values are given and the significance level was p < 0.05.
www.nature.com/scientificreports/
8Scientific RepoRts | 7: 3398  | DOI:10.1038/s41598-017-03629-5
these were decreased in the high glucosinolate group. In the inflamed joint, changes in the permeability of the 
synovium have been described, whereby increases in protein and solute concentration within the joint cavity have 
been observed31, 32. Resolution of aberrant synovial permeability by the high glucosinolate diet may offer one pos-
sible explanation for a reduction in the number of plasma proteins observed in this group, though this remains 
to be confirmed. Furthermore, a number of the proteins highlighted in our study (table 3) have been reported in 
human OA synovial fluid previously33–36.
Common plasma proteins aside, there were a number of interesting proteins decreased in abundance with the 
high glucosinolate diet including NBL1, CALR, SMARCC1 and type VI collagen. NBL1 is an antagonist of bone 
morphogenetic proteins (BMPs), key in cartilage homeostasis. Increased gene expression of NBL1 in cartilage is 
reported in mouse and rat models of OA and in human OA cartilage37–40. Calreticulin has functions outside of 
calcium regulation41. Calreticulin is increased in the plasma and synovial fluid of RA patients and this correlated 
with swollen joint count and disease activity score42. SMARCC1 is a regulator of gene transcription through 
chromatin remodelling, and is found in exosomes in cancer with no reported function in the joint43–45. Type VI 
collagen is a structural component of the perichondral matrix within articular cartilage. It has been reported in 
synovial fluid, with no significant difference between OA and control33. Methyltransferase-like 18 (METTL18) 
was significantly increased in abundance in the high glucosinolate group. It is a putative methyltransferase, and 
interacts with molecular chaperones46. Individual neopeptides were not reproducibly identified across all samples 
and this technology requires further development to be conclusive.
Gene expression in either cartilage or fat was not significantly different between groups when data were 
adjusted for multiple testing. Genes shown to be significant in unadjusted data are therefore of uncertain 
importance.
The collagen degradation biomarker Coll 2-1 has previously been shown to decrease after supplementation 
with a form of curcumin47, however only at the 85 day time point and not at the earlier 14 day time point.
Validated diet diaries showed that patients consumed similar levels of energy, fat, protein and fibre during 
the intervention. The high glucosinolate group consumed significantly higher levels of vitamin C, likely due to 
the high vitamin C content of broccoli. We therefore cannot rule out the contribution of vitamin C to the effects 
observed in the study. Future studies involving broccoli intake should include a control for vitamin C levels.
The interaction of GST genotype and ITC metabolism measured as rate of urinary secretion has been reported 
previously with differing associations13, 48–50. It has been suggested that specific GST null genotypes may confer a 
protective effect through a lowered rate of metabolism that extends tissue exposure time. Our cohort showed no 
associations of genotype with study outcomes though numbers in each subgroup were small (data not shown).
Limitations. Our study was a proof-of-principle study and limitations of the trial design were the short inter-
vention time and unspecified timing of broccoli intake. These limitations and/or the use of end-stage OA patients 
whose tissue gene expression maybe beyond modification by dietary intervention, may have contributed to the 
small changes in gene expression observed. Similarly, cartilage degradation rates in vitro were likely affected by 
rapid metabolism of dietary SFN in these cultures. The link between ITCs in the joint and changes in the synovial 
fluid may be indirect and this requires further investigation.
Conclusion
This is the first human study to show that increased broccoli intake results in ITC uptake into the joint, with 
concomitant changes in the joint. Coupled with our earlier data showing efficacy of SFN in both in vitro and in 
vivo laboratory models of OA, this supports the need for an appropriately designed clinical trial to determine the 
impact of dietary SFN in OA.
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